摘要
目的:探讨Ⅰ-Ⅳ期肺腺鳞癌患者的预后及其影响因素。方法:回顾性分析2002年1月至2012年12月四川省肿瘤医院收治肺腺鳞癌患者的临床资料,对影响其预后的各因素进行了单因素及多因素分析。结果:全组患者1、3、5年生存率分别为62.5%、31.2%和10.4%,中位生存期为21.0个月。单因素分析显示Ⅰ-Ⅱ期患者术后进行了辅助化疗与术后未进行辅助化疗的PFS及OS比较,没有显示出进行辅助化疗与生存之间有相关性。而对于进行了手术及术后辅助治疗的不同分期的患者,Ⅰ-Ⅱ期的患者较Ⅲ期的患者显示出生存获益(P=0.057)。而Ⅲ期的术后患者术后辅助化疗是影响预后的重要因素(P<0.05)。对于局部晚期无法手术的患者和晚期的患者,在治疗中有无联合放疗、中位生存时间没有差异性。多因素分析也更进一步证实分期为影响腺鳞癌预后的独立预后因素。结论:肺腺鳞癌整体预后差。是否进行手术、术后治疗和患者分期是其预后相关因素。Ⅲ期肺腺鳞癌患者可从术后辅助化疗中获益。
Objective To investigate the prognostic factors in the stage I to stage IV adenosquamous lung carcinoma, and its influencing factors. Methods ： Clinical data of patients diagnosed with adenosquamous lung carcinoma affecting prognosis was evaluated using univariate and multivariate analyses. Results ： The 1 ,3 and 5 - year survival rates were 62.5% ,31.2% and 10. 4 % , respectively, and the median survival time was 2 1 .0 months. Single factor a-nalysis showed that the I - II patients whether performed postoperative adjuvant chemotherapy, PFS and OS had no correlation. For surgery and postoperative adjuvant therapy in patients with different stages,early stage patients showed a survival benefit（P =0.057）. Postoperative adjuvant chemotherapy in stage IH patients was an important prognostic factor（P 〈0. 05） . In multivariate analysis clinical stage was the independent prognostic factor. Conclusion ： The overall survival rate of adenosquamous lung carcinoma was low. Stage IH may have benefit from adjuvant chemotherapy.
出处
《现代肿瘤医学》
CAS
2016年第21期3404-3408,共5页
Journal of Modern Oncology
关键词
肺腺鳞癌
手术治疗
辅助化疗
预后
治疗方式
adenosquamous lung carcinoma,surgical treatment,adjuvant chemotherapy,prognosis,therapy methods
